Digital
29th - 30th October, 2020

4th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress (Time Zone - GREENWHICH MEAN TIME(GMT))

40+
Speakers
10+
Networking Hours
12
Sessions
200+
Attendees

In the past decade, many scientific breakthroughs have been achieved through research including success in recent years of cancer immunotherapy with monoclonal antibodies, cancer vaccines, adoptive cell therapy and immune-checkpoint therapy. Personalized immunotherapy with various combinations will be the next promising strategy for the future cancer treatment direction.

users

30+ experts from academia and industry will be presenting their current work in Immuno-Oncology, Latest updates on regulatory guidelines and approvals, Validation markers for tumor-derived T-cell subpopulations, NextGen T-Cell and CAR-T Cell therapy, Personalized Medicine, Biomarkers and Cancer Immunotherapy

users

Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.

users

Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, Validation methods and innovative tools in IO Discovery, Oral T-Cell Therapies for the Treatment of Cancer Patients and Discovery of novel bispecific antibody molecules to boost anti-tumor immunity

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 29th - 30th October 2020 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

WHAT TO EXPECT

Why Attend?

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Sessions 

Key Highlights

  • Updates in development of monoclonal antibodies, ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Biomarkers and Cancer Vaccines
  • CAR-T cell therapy, T Cell Therapy
  • Tumor microenvironment
  • Oncolytic Viruses
  • Microbiome in Cancer Immunotherapy

CONFERENCE AGENDA
Advances in IO
Personalized Immunotherapy, Vaccines and Oncolytic Viral Therapy
CONFERENCE SPEAKERS
Advisors
Stefan Glueck
Stefan Glueck
Ex- Vice President, Global Head Franchise Oncology, Regeneron
Sophia Karagiannis
Sophia Karagiannis
Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK
Speakers
Roy Baynes
Roy Baynes
Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories
Bruno Tullia
Bruno Tullia
Assistant Professor, Immunology, University of Pittsburgh
Illip Burmester, Ph.D.
Illip Burmester, Ph.D.
Scientific Sales Support Europe, Proteome Sciences
David Gilham
David Gilham
Vice President, R&D, Celyad, UK
John Maher
John Maher
Scientific Founder and Chief Scientific Officer, Leucid Bio
Sheeba Irshad
Sheeba Irshad
CRUK Clinician Scientist & Honorary Medical Oncologist, Guys Hospital, UK
Will Arends
Will Arends
Chartered (UK) and European Patent Attorney, Marks & Clerk, UK
Markus Zettl
Markus Zettl
Director, Immuno-Oncology , Pieris Pharmaceuticals, Germany
SPONSORS
Leading Partner
example-image

GenScript

example-image

Personalis

Gold
example-image

Proteome Sciences

Silver
example-image

Miltenyi Biotec

example-image

Ultivue

Speaking Partner
example-image

PromoCell

example-image

TransCure bioServices

example-image

MBL International

example-image

HalioDx

example-image

Marks & Clerk

example-image

PHC Group

example-image

Crown Bioscience

Primary Partner
example-image

Imaging Endpoints

example-image

Thermo Fisher Scientific

example-image

Aquila BioMedical

example-image

Horizon Discovery

Exhibition Partner
example-image

Mi-mAbs

example-image

KDBIO

example-image

Synthace

PARTNERS
Supporting Association
MabDesign

MabDesign

One Nucleus

One Nucleus

Media Partners
example-image

Technology Networks

example-image

Pharma Journalist

example-image

PharmaTutor

example-image

GEN

example-image

MedNous

example-image

Medical events guide

NEWS
PAST EVENT GALLERY